ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
Avatar

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo

By ASH 2022 Conference Coverage FEATURING Eytan Stein
By ASH 2022 Conference Coverage FEATURING Eytan Stein
160 views
December 16, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Leukemia
10:42
ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in…

Feat. J. Brown
05:06
ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Patients With R/R Ph+ ALL …

Feat. W. Macaron
03:41
ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

Feat. G. Borthakur
11:00
ASH 2022 Conference Coverage

ASH 2022 Updates and Highlights in CML

Feat. E. Atallah
14:41
ASH 2022 Conference Coverage

Clinical Implications of the QUAZAR AML-001 Trial: Oral AZA Maintena…

Feat. P. Michael
19:04
ASH 2022 Conference Coverage

ASH 2022: Real-World Comparison of Time to Next Treatment for Patien…

Feat. R. Jacobs
07:16
ASH 2022 Conference Coverage

CAPTIVATE Study Updates: CLL Treatment Outcomes After Undetectable M…

Feat. C. Tam
14:37
ASH 2022 Conference Coverage

ASH 2022 Results of the ASC4MORE Study: Asciminib Add-On to Imatinib…

Feat. G. Saglio
11:30
ASH 2022 Conference Coverage

ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients T…

Feat. A. Jain
06:57
ASH 2022 Conference Coverage

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targe…

Feat. A. Danilov
13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
10:41
ASH 2022 Conference Coverage

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteri…

Feat. N. Short
06:22
ASH 2022 Conference Coverage

ASH 2022 The Addition of Inotuzumab Ozogamicin to Hyper-CVAD + Blina…

Feat. N. Short
07:38
ASH 2022 Conference Coverage

ASH 2022 Ponatinib & Blinatumomab for Pts With Newly Diagnosed P…

Feat. N. Short
11:05
ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Stu…

Feat. D. DeAngelo
09:45
ASH 2022 Conference Coverage

ASH 2022 Treatment of CLL-Associated Autoimmune Cytopenias and Outco…

Feat. K. Rogers
11:10
ASH 2022 Conference Coverage

ASH 2022 Updated Phase 2b Results of Venetoclax With FLAG-IDA in R/R…

Feat. M. Konopleva
08:14
ASH 2022 Conference Coverage

ASH 2022 Single vs. Double Induction With "7+3" Containing…

Feat. C. Röllig
07:48
ASH 2022 Conference Coverage

ASH 2022 Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Fe…

Feat. C. Röllig
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
11:12
ASH 2022 Conference Coverage

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

Feat. J. Miller
08:00
ASH 2022 Conference Coverage

ASH 2022 Phase III ASAP Trial Results: Sequential Conditioning &…

Feat. J. Schetelig
15:43
ASH 2022 Conference Coverage

ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Im…

Feat. N. Russell
20:03
ASH 2022 Conference Coverage

ASH 2022: Post-Remission Outcomes in Patients With AML Are Similar B…

Feat. M. Hochman
09:54
ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

Feat. A. Hoover
07:05
ASH 2022 Conference Coverage

ASH 2022: Lintuzumab-Ac225 in Combination With Intensive Chemo Yield…

Feat. S. Abedin
10:28
ASH 2022 Conference Coverage

ASH 2022 Phase 1 Study With the Novel Bcl-2 Inhibitor BGB-11417 as M…

Feat. C. Cheah
06:20
ASH 2022 Conference Coverage

Consolidation With Allogeneic HCT Improved Survival Outcomes of Adul…

Feat. I. Aldoss
16:32
ASH 2022 Conference Coverage

ASH 2022 Phase 3 GLOW Study: Residual Disease Kinetics Among CLL Pat…

Feat. C. Utoft Niemann
04:07
ASH 2022 Conference Coverage

ASH 2022 Novel Combination of Clinical Menin Inhibitor Ziftomenib an…

Feat. S. Balasubramanian
09:33
ASH 2022 Conference Coverage

ASH 2022 4-Year Follow-up Data on Combined Ibrutinib and Venetoclax …

Feat. N. Jain
05:38
ASH 2022 Conference Coverage

ASH 2022 Preclinical In Vivo Activity of the Menin Inhibitor Ziftome…

Feat. S. Tasian
06:23
ASH 2022 Conference Coverage

ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Indu…

Feat. A. Fathi
06:04
ASH 2022 Conference Coverage

ASH 2022 Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibruti…

Feat. S. Stilgenbauer
05:12
ASH 2022 Conference Coverage

ASH 2022 Asciminib as Initial Therapy for Patients With CML-CP: H. J…

Feat. E. Atallah
09:42
ASH 2022 Conference Coverage

Transplant in AML With MRD: Proceed or Defer?

Feat. C. Craddock
15:42
ASH 2022 Conference Coverage

ASH 2022: Reduced Venetoclax Exposition to 7 Days of Azacitidine Is …

Feat. C. Willekens
07:37
ASH 2022 Conference Coverage

ASH 2022: More Than 10 Years Follow-Up of Frontline TKI Therapy in P…

Feat. F. Haddad
07:41
ASH 2022 Conference Coverage

ASH 2022 Effectiveness of TKIs in Patients With CML-CP After Two or …

Feat. D. Žáčková
08:19
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…

Feat. N. Shah
08:12
ASH 2022 Conference Coverage

ASH 2022 Final Analysis Results From the InformCLL Registry: Real-Wo…

Feat. N. Ghosh
11:38
ASH 2022 Conference Coverage

ASH 2022 ECOG-ACRIN-E1910 Randomized Phase III NCTN Trial: Blinatumo…

Feat. M. Litzow
07:30
ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Sympt…

Feat. E. Padron
08:00
ASH 2022 Conference Coverage

ASH 2022 Contemporary Guidelines for Diagnosis and Genomic Classific…

Feat. I. Iacobucci
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
04:55
ASH 2022 Conference Coverage

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

Feat. E. Stein
11:52
ASH 2022 Conference Coverage

ASH 2022 Real-World OS and TTNT by 1L Therapy (BTKi and BCL2i) in Pa…

Feat. W. Archibald, C. Wang
05:33
ASH 2022 Conference Coverage

ASH 2022: Phase II Study of Inotuzumab Ozogamicin for the Treatment …

Feat. J. Senapati
10:39
ASH 2022 Conference Coverage

ASH 2022: Splicing Factor Gene Mutations Do Not Affect Outcomes in N…

Feat. J. Senapati
07:43
ASH 2022 Conference Coverage

ASH 2022 The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable …

Feat. G. Issa
08:57
ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

Feat. J. Bewersdorf